Quizartinib, an FMS-like tyrosine kinase 3 (FLT3) receptor tyrosine kinase inhibitor, has shown promising results in patients with relapsed refractory AML, particularly those patients harboring an FLT3-internal tandem duplication (ITD). Here, FLT3 is linked to acute myeloid leukemia.